药明康德
(603259)
| 流通市值：2684.50亿 | | | 总市值：3238.57亿 |
| 流通股本：24.73亿 | | | 总股本：29.84亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 35,905,237,313.79 | 35,131,309,638.47 | 29,438,763,964.44 | 21,485,198,395.79 |
| 交易性金融资产 | 7,479,221,505.81 | 5,806,211,811.42 | 3,560,951,646.05 | 2,942,419,172.43 |
| 衍生金融资产 | 116,808,345.33 | 68,657,103.15 | 1,825,522.26 | 2,618,674 |
| 应收票据及应收账款 | 7,707,674,171.14 | 7,281,326,326.92 | 8,464,159,356.01 | 7,046,591,939.48 |
| 其中：应收票据 | 6,737,203.77 | 18,672,249.95 | 24,070,487.2 | 14,249,003.27 |
| 应收账款 | 7,700,936,967.37 | 7,262,654,076.97 | 8,440,088,868.81 | 7,032,342,936.21 |
| 预付款项 | 317,915,447.87 | 246,628,413.97 | 249,903,440.34 | 215,891,788.78 |
| 其他应收款合计 | 346,414,417.16 | 724,565,155.08 | 493,409,032.07 | 497,343,390.63 |
| 其中:应收利息 | 101,013,056.9 | 28,476,379.02 | 145,798,546.89 | 100,885,861.23 |
| 存货 | 9,965,880,371.58 | 8,993,244,894.24 | 7,843,744,998.67 | 7,151,214,786.47 |
| 合同资产 | 528,212,738.24 | 469,517,512.56 | 819,019,237.79 | 825,681,661.85 |
| 一年内到期的非流动资产 | 1,399,386,889.12 | 1,402,987,153.42 | 742,342,496.85 | 735,642,342.11 |
| 其他流动资产 | 1,402,557,817.74 | 1,526,562,259.73 | 1,682,457,981.21 | 1,503,368,171.42 |
| 流动资产合计 | 65,169,309,017.78 | 61,677,055,890.49 | 53,812,305,105.12 | 42,588,730,423.99 |
| 非流动资产: | | | | |
| 长期股权投资 | 2,275,267,437.71 | 2,144,876,912.07 | 1,943,078,812.64 | 1,890,460,225.96 |
| 其他非流动金融资产 | 8,464,145,695 | 8,131,208,431.7 | 8,350,830,303.38 | 8,504,412,209.13 |
| 固定资产 | 19,517,849,361.35 | 19,999,931,768.14 | 19,411,072,560.47 | 18,672,287,350.64 |
| 在建工程 | 6,709,257,892.76 | 5,875,518,226.97 | 5,848,288,554.04 | 6,616,940,095.95 |
| 生产性生物资产 | 1,024,158,000 | 1,013,273,000 | 1,085,705,000 | 1,065,099,000 |
| 使用权资产 | 729,801,197.15 | 763,114,562.83 | 860,206,952.34 | 930,348,161.05 |
| 无形资产 | 1,254,435,323.44 | 1,280,523,344.96 | 1,396,909,976.18 | 1,482,798,029.85 |
| 商誉 | 863,384,053.29 | 864,388,850.17 | 865,960,177.6 | 971,608,125.55 |
| 长期待摊费用 | 337,909,304.42 | 366,834,780.31 | 412,493,218.41 | 446,000,817.06 |
| 递延所得税资产 | 565,719,437.59 | 531,296,901.24 | 512,939,841.3 | 511,074,087.89 |
| 其他非流动资产 | 503,244,620.76 | 472,945,910.23 | 106,344,914.59 | 144,021,375.17 |
| 非流动资产合计 | 42,245,172,323.47 | 41,443,912,688.62 | 40,793,830,310.95 | 41,235,049,478.25 |
| 资产总计 | 107,414,481,341.25 | 103,120,968,579.11 | 94,606,135,416.07 | 83,823,779,902.24 |
| 流动负债: | | | | |
| 短期借款 | 5,977,731,732.75 | 5,986,138,418.73 | 5,281,547,061.1 | 5,797,353,028.01 |
| 衍生金融负债 | 90,740,849.75 | - | 2,855,672.55 | - |
| 应付票据及应付账款 | 2,851,372,623.18 | 2,449,523,876.15 | 2,272,672,131.75 | 2,158,849,287.23 |
| 其中：应付票据 | 13,482,000 | - | - | - |
| 应付账款 | 2,837,890,623.18 | 2,449,523,876.15 | 2,272,672,131.75 | 2,158,849,287.23 |
| 合同负债 | 2,764,250,761.82 | 2,709,159,889.23 | 2,565,673,751.55 | 2,227,078,534.78 |
| 应付职工薪酬 | 1,267,117,491.99 | 2,326,308,898.74 | 2,214,297,963.72 | 1,827,364,280.26 |
| 应交税费 | 2,764,818,288.65 | 2,762,813,534.62 | 2,521,862,090.8 | 1,534,061,706.82 |
| 其他应付款合计 | 3,161,353,124.05 | 2,841,705,486.56 | 2,995,437,115.25 | 3,198,710,213.59 |
| 其中:应付利息 | 924,219.45 | 1,016,663.76 | 908,179.17 | 756,890.28 |
| 应付股利 | 23,606,550 | 23,606,550 | 23,606,550 | 25,144,176 |
| 一年内到期的非流动负债 | 164,100,660.51 | 159,618,101.21 | 180,466,661.01 | 221,763,996.1 |
| 其他流动负债 | - | - | 1,294,458,646.69 | 3,517,369,518.75 |
| 流动负债合计 | 19,041,485,532.7 | 19,235,268,205.24 | 19,438,255,302.47 | 20,518,915,049.34 |
| 非流动负债: | | | | |
| 长期借款 | 1,818,800,000 | 1,819,100,000 | 1,799,100,000 | 904,891,240.48 |
| 租赁负债 | 418,299,246.95 | 455,256,654.87 | 532,674,859 | 592,095,179.22 |
| 递延收益 | 919,451,614.16 | 948,171,287.5 | 929,903,996.84 | 959,417,342.59 |
| 递延所得税负债 | 444,815,538.54 | 415,458,829.98 | 433,703,953.06 | 439,379,335.81 |
| 非流动负债合计 | 3,601,366,399.65 | 3,637,986,772.35 | 3,695,382,808.9 | 2,895,783,098.1 |
| 负债合计 | 22,642,851,932.35 | 22,873,254,977.59 | 23,133,638,111.37 | 23,414,698,147.44 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 2,983,757,155 | 2,983,757,155 | 2,965,692,554 | 2,872,217,205 |
| 资本公积 | 33,200,448,846.31 | 33,077,292,637.94 | 31,736,772,250.87 | 23,287,828,945.4 |
| 减:库存股 | 3,838,766,784.75 | 3,842,179,016.17 | 4,535,883,010.49 | 4,600,976,294.78 |
| 其他综合收益 | -415,727,814.09 | -147,106,673.86 | 216,081,914.03 | 268,784,721.41 |
| 盈余公积 | 1,491,878,577.5 | 1,491,878,577.5 | 1,436,108,602.5 | 1,436,108,602.5 |
| 未分配利润 | 50,800,165,553.79 | 46,148,647,566.03 | 39,129,348,097.26 | 36,647,745,125.5 |
| 归属于母公司股东权益合计 | 84,221,755,533.76 | 79,712,290,246.44 | 70,948,120,408.17 | 59,911,708,305.03 |
| 少数股东权益 | 549,873,875.14 | 535,423,355.08 | 524,376,896.53 | 497,373,449.77 |
| 股东权益合计 | 84,771,629,408.9 | 80,247,713,601.52 | 71,472,497,304.7 | 60,409,081,754.8 |
| 负债和股东权益合计 | 107,414,481,341.25 | 103,120,968,579.11 | 94,606,135,416.07 | 83,823,779,902.24 |
| 公告日期 | 2026-04-28 | 2026-03-24 | 2025-10-27 | 2025-07-29 |
| 审计意见(境内) | | 标准无保留意见 | | |